2. Neuronal Signaling Cell Cycle/DNA Damage Others
  3. Choline Kinase Early 2 Factor (E2F) Fluorescent Dye
  4. JAS239

JAS239 is a blood-brain barrier-permeable ChoK inhibitor. JAS239 inhibits phosphocholine synthesis and reduces the expression level of E2F1 protein. JAS239 exhibits near-infrared fluorescence properties. JAS239 exerts anti-tumor activity against glioblastoma. JAS239 can be used in studies related to glioblastoma.

For research use only. We do not sell to patients.

JAS239

JAS239 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

JAS239 Related Antibodies

Top Publications Citing Use of Products

View All Choline Kinase Isoform Specific Products:

View All Isoforms
CHKα

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

JAS239 is a blood-brain barrier-permeable ChoK inhibitor. JAS239 inhibits phosphocholine synthesis and reduces the expression level of E2F1 protein. JAS239 exhibits near-infrared fluorescence properties. JAS239 exerts anti-tumor activity against glioblastoma. JAS239 can be used in studies related to glioblastoma[1][2][3].

IC50 & Target[1]

ChoK

 

E2F1

 

In Vitro

JAS239 (maximum 100 μM; 24 h) reduces the metabolic activity (a surrogate marker for cell viability) of glioblastoma (GBM) cells, and exhibits comparable potency against the F98, 9L, U-87 MG and U-251 MG cell lines under both normoxic and hypoxic conditions[2].
JAS239 (500 nM; 24-96 h) inhibits the proliferation of GBM cells by inducing cell cycle arrest and downregulating E2F-1 expression[2].
JAS239 (500 nM; 0-96 h) inhibits the proliferation of the 9L glioblastoma cell line under normoxic conditions[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

JAS239 Related Antibodies

Cell Invasion Assay[2]

Cell Line: rat F98, human U-87 MG GBM cell lines (3D spheroid assay); rat F98, 9L, human U-251 MG GBM cell lines (integrin expression analysis)
Concentration: 500 nM
Incubation Time: 16 h (3D spheroid assay)
Result: Significantly reduced track straightness (0.28 ± 0.11 vs.
0.32 ± 0.12, p < 0.0001), track length (84.0 ± 48.0 μm vs.
113.2 ± 86 μm, p < 0.0001), and average speed (0.005 ± 0.001 μm/s vs.
0.007 ± 0.004 μm/s, p < 0.0001), and induced super-diffusive cell motion in normoxic F98 spheroids.
Significantly reduced track straightness and length, and increased cell speed, with induced super-diffusive cell motion in DMOG-hypoxic F98 spheroids.
Significantly increased track length (133.0 ± 61.6 μm vs.
120.7 ± 57.7 μm, p < 0.001) and average speed (0.007 ± 0.001 μm/s vs.
0.006 ± 0.001 μm/s, p < 0.0001), with no change in track straightness, and induced super-diffusive cell motion in normoxic U-87 MG spheroids.
Resulted in track straightness and speed comparable to DMOG-only treatment, with induced super-diffusive cell motion in DMOG-hypoxic U-87 MG spheroids.
Reduced integrin α3β1 protein expression (a marker of cell mobility) in F98, 9L, and U-251 MG cells.
In Vivo

JAS239 (4 mg/kg; i.p.; once daily; 5 consecutive days) inhibits tumor growth in glioblastoma rats and mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Fischer F344 (female, weight 100-120 g, intracranial injection of 50,000 F98 GBM cells)[1]
Dosage: 4 mg/kg
Administration: intraperitoneal injection; once daily; 5 consecutive days
Result: Significantly reduced tumor growth (p < 0.05) and percentage change of tumor volume (p = 0.033) compared to controls.
Detected a significant reduction (p = 0.02) in mI/tCr ratio in treated tumors.
Noted a 32% non-significant reduction in Glx/tCr ratio.
Observed a near-significant 97% increase (p = 0.052) in (Lip + Lac)/tCr ratio.
Measured a near-significant lower mitotic index (p = 0.06) in treated tumors.
Showed non-significant reduction in tCho/tCr ratio and non-significant trend of reduction in tCho/NAA ratio.
Animal Model: Fischer F344 (female, weight 100-120 g, intracranial injection of 100,000 9L GBM cells)[1]
Dosage: 4 mg/kg
Administration: intraperitoneal injection; once daily; 5 consecutive days
Result: Observed non-significant tumor growth arrest compared to controls.
Measured the largest non-significant reduction in tCho/tCr ratio (-42%) across all models.
Detected a significant reduction (p = 0.047) in tCho/NAA ratio.
Showed non-significant trend of reduction in mI/tCr ratio and Glx/tCr ratio.
Observed a non-significant -20% change in (Lip + Lac)/tCr ratio.
Measured a lower mitotic index in treated tumors.
Animal Model: C57BL/6 (male, age 8-10 weeks, weight 20-25 g, intracranial injection of 500,000 GL261 GBM cells)[1]
Dosage: 4 mg/kg
Administration: intraperitoneal injection; once daily; 5 consecutive days
Result: Observed non-significant tumor growth arrest compared to controls.
Showed non-significant reduction in tCho/tCr ratio and non-significant trend of reduction in tCho/NAA ratio.
Detected non-significant trend of reduction in mI/tCr ratio.
Noted no significant change in Glx/tCr ratio and (Lip + Lac)/tCr ratio.
Measured a lower mitotic index in treated tumors.
Molecular Weight

505.09

Formula

C31H37ClN2O2
SMILES

OCCN1C2=C(C(C)(C)C1=C/C=C/C=C/C=C/C(C(C)(C3=C4C=CC=C3)C)=[N+]4CCO)C=CC=C2.[Cl-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

JAS239 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

JAS239JAS 239JAS-239Choline KinaseEarly 2 Factor (E2F)Fluorescent DyeCKChoKcholine phosphokinaseU-87 MGphosphatidylcholine synthesisG0/G1 cell cycle arrestglioblastoma9Lapoptosisblood-brain barriercholine kinase alphaF98U-251 MGInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
JAS239
Cat. No.:
HY-123612
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.